Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 104 entries
Sorted by: Best Match Show Resources per page
Classification of stage C carcinoma of the prostate.

The Journal of urology

Pollen JJ.
PMID: 7218474
J Urol. 1981 Apr;125(4):604. doi: 10.1016/s0022-5347(17)55131-9.

No abstract available.

Cite
Pollen JJ. Classification of stage C carcinoma of the prostate. J Urol. 1981;125(4):604doi: 10.1016/s0022-5347(17)55131-9.
Pollen, J. J. (1981). Classification of stage C carcinoma of the prostate. The Journal of urology, 125(4), 604. https://doi.org/10.1016/s0022-5347(17)55131-9
Pollen, J J. "Classification of stage C carcinoma of the prostate." The Journal of urology vol. 125,4 (1981): 604. doi: https://doi.org/10.1016/s0022-5347(17)55131-9
Pollen JJ. Classification of stage C carcinoma of the prostate. J Urol. 1981 Apr;125(4):604. doi: 10.1016/s0022-5347(17)55131-9. PMID: 7218474.
Copy Download .nbib Format: NLM
An historical perspective of the pathology and treatment.

Cancer surveys

Franks LM.
PMID: 7621468
Cancer Surv. 1995;23:303-7.

There are inner and outer gland groups in the human prostate. Benign nodular hyperplasia develops from the inner group of glands. Carcinomas arise in the outer glands and spread beyond the prostate at an early stage in the disease....

Cite
Franks LM. An historical perspective of the pathology and treatment. Cancer Surv. 1995;23:303-7
Franks, L. M. (1995). An historical perspective of the pathology and treatment. Cancer surveys, 23303-7.
Franks, L M. "An historical perspective of the pathology and treatment." Cancer surveys vol. 23 (1995): 303-7.
Franks LM. An historical perspective of the pathology and treatment. Cancer Surv. 1995;23:303-7. PMID: 7621468.
Copy Download .nbib Format: NLM
How far should we investigate and treat prostate cancer?.

The Medical journal of Australia

Sladden MJ, Dickinson JA, Thomson A.
PMID: 7695746
Med J Aust. 1994 Dec 5-19;161(11):722.

No abstract available.

Cite
Sladden MJ, Dickinson JA, Thomson A. How far should we investigate and treat prostate cancer?. Med J Aust. 1994;161(11):722
Sladden, M. J., Dickinson, J. A., & Thomson, A. (1994). How far should we investigate and treat prostate cancer?. The Medical journal of Australia, 161(11), 722.
Sladden, M J, et al. "How far should we investigate and treat prostate cancer?." The Medical journal of Australia vol. 161,11 (1994): 722.
Sladden MJ, Dickinson JA, Thomson A. How far should we investigate and treat prostate cancer?. Med J Aust. 1994 Dec 5-19;161(11):722. PMID: 7695746.
Copy Download .nbib Format: NLM
Prostate cancer.

Current therapy in endocrinology and metabolism

Garzotto M, Fair WR.
PMID: 9174811
Curr Ther Endocrinol Metab. 1997;6:582-6.

No abstract available.

Cite
Garzotto M, Fair WR. Prostate cancer. Curr Ther Endocrinol Metab. 1997;6:582-6
Garzotto, M., & Fair, W. R. (1997). Prostate cancer. Current therapy in endocrinology and metabolism, 6582-6.
Garzotto, M, and Fair, W R. "Prostate cancer." Current therapy in endocrinology and metabolism vol. 6 (1997): 582-6.
Garzotto M, Fair WR. Prostate cancer. Curr Ther Endocrinol Metab. 1997;6:582-6. PMID: 9174811.
Copy Download .nbib Format: NLM
Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.

European urology

Hugosson J, Lilja H, Lodding P, Pihl CG.
PMID: 11340286
Eur Urol. 2001 Apr;39:33-4. doi: 10.1159/000052582.

No abstract available.

Cite
Hugosson J, Lilja H, Lodding P, et al. Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. Eur Urol. 2001;39:33-4doi: 10.1159/000052582.
Hugosson, J., Lilja, H., Lodding, P., & Pihl, C. G. (2001). Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. European urology, 3933-4. https://doi.org/10.1159/000052582
Hugosson, J, et al. "Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers." European urology vol. 39 (2001): 33-4. doi: https://doi.org/10.1159/000052582
Hugosson J, Lilja H, Lodding P, Pihl CG. Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. Eur Urol. 2001 Apr;39:33-4. doi: 10.1159/000052582. PMID: 11340286.
Copy Download .nbib Format: NLM
Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias.

The Journal of urology

Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF.
PMID: 14501722
J Urol. 2003 Oct;170(4):1189-93. doi: 10.1097/01.ju.0000085675.96097.76.

PURPOSE: Surveillance, Epidemiology and End Results (SEER) data reveal an increasing incidence in the detection of moderately differentiated prostate cancer and a stable or decreasing incidence in well and poorly differentiated cancer. Plausible reasons for this phenomenon include the...

Cite
Kondylis FI, Moriarty RP, Bostwick D, et al. Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. J Urol. 2003;170(4):1189-93doi: 10.1097/01.ju.0000085675.96097.76.
Kondylis, F. I., Moriarty, R. P., Bostwick, D., & Schellhammer, P. F. (2003). Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. The Journal of urology, 170(4), 1189-93. https://doi.org/10.1097/01.ju.0000085675.96097.76
Kondylis, Filippos I, et al. "Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias." The Journal of urology vol. 170,4 (2003): 1189-93. doi: https://doi.org/10.1097/01.ju.0000085675.96097.76
Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF. Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. J Urol. 2003 Oct;170(4):1189-93. doi: 10.1097/01.ju.0000085675.96097.76. PMID: 14501722.
Copy Download .nbib Format: NLM
Current options in the management of clinical stage C prostatic carcinoma.

The Urologic clinics of North America

Fallon B, Williams RD.
PMID: 2219582
Urol Clin North Am. 1990 Nov;17(4):853-66.

The evaluation of clinical stage C prostatic cancer has been enhanced by advances in staging modalities over the past 15 years. Better staging of the local lesion is possible with transrectal ultrasound-guided multiple biopsies of the prostate and its...

Cite
Fallon B, Williams RD. Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am. 1990;17(4):853-66
Fallon, B., & Williams, R. D. (1990). Current options in the management of clinical stage C prostatic carcinoma. The Urologic clinics of North America, 17(4), 853-66.
Fallon, B, and Williams, R D. "Current options in the management of clinical stage C prostatic carcinoma." The Urologic clinics of North America vol. 17,4 (1990): 853-66.
Fallon B, Williams RD. Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am. 1990 Nov;17(4):853-66. PMID: 2219582.
Copy Download .nbib Format: NLM
Carcinoma of the prostate: treatment options and controversies.

Virginia medical

Kuban DA, el-Mahdi AM.
PMID: 3321737
Va Med. 1987 Nov;114(11):674-7.

No abstract available.

Cite
Kuban DA, el-Mahdi AM. Carcinoma of the prostate: treatment options and controversies. Va Med. 1987;114(11):674-7
Kuban, D. A., & el-Mahdi, A. M. (1987). Carcinoma of the prostate: treatment options and controversies. Virginia medical, 114(11), 674-7.
Kuban, D A, and el-Mahdi, A M. "Carcinoma of the prostate: treatment options and controversies." Virginia medical vol. 114,11 (1987): 674-7.
Kuban DA, el-Mahdi AM. Carcinoma of the prostate: treatment options and controversies. Va Med. 1987 Nov;114(11):674-7. PMID: 3321737.
Copy Download .nbib Format: NLM
A uniform histopathologic grading system for prostate cancer. Subcommittee on Diagnostic Nomenclature, Prostate Cancer Working Group, Organ Systems Program.

Human pathology

Gardner WA, Coffey D, Karr JP, Chiarodo A, Epstein J, McNeal JE, Miller G.
PMID: 3335387
Hum Pathol. 1988 Jan;19(1):119-20. doi: 10.1016/s0046-8177(88)80330-7.

No abstract available.

Cite
Gardner WA, Coffey D, Karr JP, et al. A uniform histopathologic grading system for prostate cancer. Subcommittee on Diagnostic Nomenclature, Prostate Cancer Working Group, Organ Systems Program. Hum Pathol. 1988;19(1):119-20doi: 10.1016/s0046-8177(88)80330-7.
Gardner, W. A., Coffey, D., Karr, J. P., Chiarodo, A., Epstein, J., McNeal, J. E., & Miller, G. (1988). A uniform histopathologic grading system for prostate cancer. Subcommittee on Diagnostic Nomenclature, Prostate Cancer Working Group, Organ Systems Program. Human pathology, 19(1), 119-20. https://doi.org/10.1016/s0046-8177(88)80330-7
Gardner, W A, et al. "A uniform histopathologic grading system for prostate cancer. Subcommittee on Diagnostic Nomenclature, Prostate Cancer Working Group, Organ Systems Program." Human pathology vol. 19,1 (1988): 119-20. doi: https://doi.org/10.1016/s0046-8177(88)80330-7
Gardner WA, Coffey D, Karr JP, Chiarodo A, Epstein J, McNeal JE, Miller G. A uniform histopathologic grading system for prostate cancer. Subcommittee on Diagnostic Nomenclature, Prostate Cancer Working Group, Organ Systems Program. Hum Pathol. 1988 Jan;19(1):119-20. doi: 10.1016/s0046-8177(88)80330-7. PMID: 3335387.
Copy Download .nbib Format: NLM
Intermediate-risk Prostate Cancer: Stratification and Management.

European urology oncology

Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV.
PMID: 32303478
Eur Urol Oncol. 2020 Jun;3(3):270-280. doi: 10.1016/j.euo.2020.03.002. Epub 2020 Apr 14.

CONTEXT: Intermediate-risk prostate cancer consists of a highly heterogeneous group of patients. Owing to this heterogeneity and variable prognoses, it is challenging to provide uniform treatment recommendations for men in this group.OBJECTIVE: To review the current literature regarding the...

Cite
Preisser F, Cooperberg MR, Crook J, et al. Intermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol. 2020;3(3):270-280doi: 10.1016/j.euo.2020.03.002.
Preisser, F., Cooperberg, M. R., Crook, J., Feng, F., Graefen, M., Karakiewicz, P. I., Klotz, L., Montironi, R., Nguyen, P. L., & D'Amico, A. V. (2020). Intermediate-risk Prostate Cancer: Stratification and Management. European urology oncology, 3(3), 270-280. https://doi.org/10.1016/j.euo.2020.03.002
Preisser, Felix, et al. "Intermediate-risk Prostate Cancer: Stratification and Management." European urology oncology vol. 3,3 (2020): 270-280. doi: https://doi.org/10.1016/j.euo.2020.03.002
Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV. Intermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol. 2020 Jun;3(3):270-280. doi: 10.1016/j.euo.2020.03.002. Epub 2020 Apr 14. PMID: 32303478.
Copy Download .nbib Format: NLM
Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.

Cancer biology & therapy

Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R.
PMID: 30339521
Cancer Biol Ther. 2019;20(2):219-226. doi: 10.1080/15384047.2018.1523849. Epub 2018 Oct 19.

Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer, as...

Cite
Ikeda S, Elkin SK, Tomson BN, et al. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2018;20(2):219-226doi: 10.1080/15384047.2018.1523849.
Ikeda, S., Elkin, S. K., Tomson, B. N., Carter, J. L., & Kurzrock, R. (2019). Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer biology & therapy, 20(2), 219-226. https://doi.org/10.1080/15384047.2018.1523849
Ikeda, Sadakatsu, et al. "Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing." Cancer biology & therapy vol. 20,2 (2019): 219-226. doi: https://doi.org/10.1080/15384047.2018.1523849
Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2019;20(2):219-226. doi: 10.1080/15384047.2018.1523849. Epub 2018 Oct 19. PMID: 30339521; PMCID: PMC6343723.
Copy Download .nbib Format: NLM
[No title available]

Presse medicale (Paris, France : 1983)

Monnier L, Culine S, Cormier L.
PMID: 28549631
Presse Med. 2017 Oct;46(10):940-947. doi: 10.1016/j.lpm.2017.03.007. Epub 2017 May 23.

The high-risk group of prostate cancers is a heterogeneous group. A better definition of the criteria could bring a better selection of patients' selection in the combined local treatment or even in the general treatment. A treatment of these...

Cite
Monnier L, Culine S, Cormier L. Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non). . Presse Med. 2017;46(10):940-947doi: 10.1016/j.lpm.2017.03.007.
Monnier, L., Culine, S., & Cormier, L. (2017). Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non). . Presse medicale (Paris, France : 1983), 46(10), 940-947. https://doi.org/10.1016/j.lpm.2017.03.007
Monnier, Laurie, et al. "Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non)." . Presse medicale (Paris, France : 1983) vol. 46,10 (2017): 940-947. doi: https://doi.org/10.1016/j.lpm.2017.03.007
Monnier L, Culine S, Cormier L. Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non). . Presse Med. 2017 Oct;46(10):940-947. doi: 10.1016/j.lpm.2017.03.007. Epub 2017 May 23. French. PMID: 28549631.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 104 entries